Targeted chemotherapy infusion aims to control advanced stomach cancer
NCT ID NCT07655024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether delivering FOLFOX chemotherapy directly into the arteries feeding the tumor can help control advanced stomach or gastroesophageal junction cancer. The study includes 31 adults who cannot have surgery due to frailty or other health issues. The main goal is to see if this approach improves quality of life and slows disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOX chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced gastric cancer who cannot have surgery, potentially improving tumor control and quality of life.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply broadly. The procedure carries risks like infection, bleeding, or allergic reactions, and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of General Surgery, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St, West-city District, Beijing, China
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••